Austrian biotech HeartBeat.bio secures €4.5M for cardioid drug discovery platform
This article covers news from Austrian biotech startup HeartBeat.bio, a Molecular Devices collaborator about securing €4.5 million in a Pre-Series A funding round. The funding will support the completion of HeartBeat.bio's cardioid drug discovery platform, focusing on drug-induced and genetic cardiomyopathies, myocardial infarction, and fibrosis.
The platform leverages Molecular Devices' CellXpress.ai automated cell culture system to cover target identification, disease modeling, hit identification, lead compound development, drug profiling, and clinical trials-in-a-dish, expediting the development of first-in-class drugs in a more cost-effective manner with higher clinical success rates.